Mari Campbell1, Alex Clarke2, Andrew Symes3, Sarita Workman3, Hans Stauss3, A David Webster3. 1. UCL Institute of Immunity and Transplantation, Department of Clinical Immunology-2nd Floor, Royal Free London NHS Foundation Trust, Pond Street, London, NW3 2QG, UK. mari.campbell@nhs.net. 2. Department of Health and Social Sciences, University of the West of England, Bristol, UK. 3. UCL Institute of Immunity and Transplantation, Department of Clinical Immunology-2nd Floor, Royal Free London NHS Foundation Trust, Pond Street, London, NW3 2QG, UK.
Abstract
PURPOSE: Patients with primary antibody deficiency report poorer quality of life and higher rates of anxiety and depression than the general population. Cognitive-behavioral therapy has been shown to be a valuable treatment for patients with other long-term physical health conditions, improving well-being and enabling them to manage their symptoms more effectively. The aim of this project was to establish the feasibility and effectiveness of providing cognitive-behavioral based therapy to patients with primary antibody deficiency. METHODS: Forty-four patients completed a course of psychological therapy. Participants completed a series of self-report measures examining psychological and physical health, and service usage, prior to starting treatment and following their final session. They also provided feedback on their experience of treatment. RESULTS: Patients showed improvements in anxiety, depression, insomnia and fatigue. There was a high level of acceptability of the service and the potential for long-term cost savings to the NHS. CONCLUSION: Psychological therapy based on the cognitive-behavioral model of treatment appears to be a valuable treatment for patients with primary antibody deficiency and comorbid mental health difficulties.
PURPOSE:Patients with primary antibody deficiency report poorer quality of life and higher rates of anxiety and depression than the general population. Cognitive-behavioral therapy has been shown to be a valuable treatment for patients with other long-term physical health conditions, improving well-being and enabling them to manage their symptoms more effectively. The aim of this project was to establish the feasibility and effectiveness of providing cognitive-behavioral based therapy to patients with primary antibody deficiency. METHODS: Forty-four patients completed a course of psychological therapy. Participants completed a series of self-report measures examining psychological and physical health, and service usage, prior to starting treatment and following their final session. They also provided feedback on their experience of treatment. RESULTS:Patients showed improvements in anxiety, depression, insomnia and fatigue. There was a high level of acceptability of the service and the potential for long-term cost savings to the NHS. CONCLUSION: Psychological therapy based on the cognitive-behavioral model of treatment appears to be a valuable treatment for patients with primary antibody deficiency and comorbid mental health difficulties.
Entities:
Keywords:
Primary antibody deficiency; cognitive-behavioral therapy; immunoglobulin replacement therapy; mental health; quality of life
Authors: Alexandra C Battersby; Helen Braggins; Mark S Pearce; Fiona McKendrick; Mari Campbell; Siobhan Burns; Catherine M Cale; David Goldblatt; Andrew R Gennery Journal: J Clin Immunol Date: 2019-03-13 Impact factor: 8.317
Authors: Olivia R Manusama; Nico J M van Beveren; P Martin van Hagen; Hemmo A Drexhage; Virgil A S H Dalm Journal: J Clin Immunol Date: 2022-01-19 Impact factor: 8.317